Search results for "PROMOTER REGION"

showing 10 items of 443 documents

Lack of TERT promoter mutations in melanomas with extensive regression

2015

AdultMale0301 basic medicineTelomeraseSkin NeoplasmsDermatologyTert promoter030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinemedicineHumansPromoter Regions GeneticMelanomaTelomeraseAgedbusiness.industryMelanomaCase-control studyMiddle Agedmedicine.diseaseRegressionNeoplasm regression030104 developmental biologyNeoplasm Regression SpontaneousCase-Control StudiesMutationMutation (genetic algorithm)Cancer researchFemalebusinessJournal of the American Academy of Dermatology
researchProduct

Urea cycle dysregulation in non-alcoholic fatty liver disease.

2018

Background & Aims: In non-alcoholic steatohepatitis (NASH), the function of urea cycle enzymes (UCEs) may be affected, resulting in hyperammonemia and the risk of disease progression. We aimed to determine whether the expression and function of UCEs are altered in an animal model of NASH and in patients with non-alcoholic fatty liver disease (NAFLD), and whether this process is reversible. Methods: Rats were first fed a high-fat, high-cholesterol diet for 10 months to induce NASH, before being switched onto a normal chow diet to recover. In humans, we obtained liver biopsies from 20 patients with steatosis and 15 with NASH. Primary rat hepatocytes were isolated and cultured with free fatty …

AdultMale0301 basic medicinemedicine.medical_specialtyCarbamoyl-Phosphate Synthase (Ammonia)Ornithine transcarbamylase03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAmmoniaGlutamate-Ammonia LigaseNon-alcoholic Fatty Liver DiseaseInternal medicineGene expressionmedicineAnimalsHumansUreaRats WistarPromoter Regions GeneticCells CulturedOrnithine CarbamoyltransferaseAgedHepatologyChemistryFatty liverHyperammonemiaDNA MethylationMiddle Agedmedicine.diseaseRats030104 developmental biologyEndocrinologyLiverUrea cycleHepatocytesUreaFemale030211 gastroenterology & hepatologySteatohepatitisSteatosis
researchProduct

Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres.

2010

Abstract Purpose: Quantitative methylation-specific tests suggest that not all cells in a glioblastoma with detectable promoter methylation of the O6-methylguanine DNA methyltransferase (MGMT) gene carry a methylated MGMT allele. This observation may indicate cell subpopulations with distinct MGMT status, raising the question of the clinically relevant cutoff of MGMT methylation therapy. Epigenetic silencing of the MGMT gene by promoter methylation blunts repair of O6-methyl guanine and has been shown to be a predictive factor for benefit from alkylating agent therapy in glioblastoma. Experimental Design: Ten paired samples of glioblastoma and respective glioblastoma-derived spheres (GS), c…

AdultMaleCancer ResearchMethyltransferaseDNA repairBiologyDNA methyltransferaseGene dosageO(6)-Methylguanine-DNA MethyltransferaseGene FrequencyTumor Cells CulturedHumansPromoter Regions GeneticneoplasmsAgedAged 80 and overBrain NeoplasmsO-6-methylguanine-DNA methyltransferaseMethylationDNA MethylationMiddle AgedMolecular biologydigestive system diseasesChromatinOncologyCpG siteDNA methylationFemaleGlioblastomaClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Demethylation treatment restores hic1 expression and impairs aggressiveness of head and neck squamous cell carcinoma.

2010

Promoter hypermethylation of tumor suppressor genes is a common feature of primary cancer cells. However, at date the somatic epigenetic events that occur in head and neck squamous cell carcinoma (HNSCC) tumorigenesis are not yet been well defined. In the present study we analysed the methylation status of the gene hypermethylated in cancer-1 (hic1), a gene located on chromosome 17p13.3, a region frequently lost in HNSCC. We analysed 22 HNSCC samples and three cell lines using methylation specific PCR (MSP). We found hic1 methylated in 21 out of 22 samples and in all three cell lines. Treatment of the cell lines with the demethylating agent 5-Azacytidin (5-Aza) resulted in the demethylation…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyAntimetabolites AntineoplasticTumor suppressor geneBisulfite sequencingKruppel-Like Transcription FactorsBiologymedicine.disease_causechemistry.chemical_compoundCell Line TumormedicineHumansGenes Tumor SuppressorNeoplasm InvasivenessPromoter Regions GeneticneoplasmsAgedMethylationDNA MethylationMiddle Agedmedicine.diseaseHead and neck squamous-cell carcinomaDemethylating agentGene Expression Regulation Neoplasticstomatognathic diseasesOncologychemistryEpidermoid carcinomaHead and Neck NeoplasmsCancer cellCancer researchAzacitidineCarcinoma Squamous CellFemaleOral SurgeryCarcinogenesisOral oncology
researchProduct

Lithium and GSK3-β promoter gene variants influence white matter microstructure in bipolar disorder

2013

Lithium is the mainstay for the treatment of bipolar disorder (BD) and inhibits glycogen synthase kinase 3-beta (GSK3-beta). The less active GSK3-beta promoter gene variants have been associated with less detrimental clinical features of BD. GSK3-beta gene variants and lithium can influence brain gray matter structure in psychiatric conditions. Diffusion tensor imaging (DTI) measures of white matter (WM) integrity showed widespred disruption of WM structure in BD. In a sample of 70 patients affected by a major depressive episode in course of BD, we investigated the effect of ongoing long-term lithium treatment and GSK3-beta promoter rs334558 polymorphism on WM microstructure, using DTI and …

AdultMaleCorpus callosumNerve Fibers MyelinatedWhite matterGlycogen Synthase Kinase 3GSK3-β03 medical and health sciences0302 clinical medicineCorona radiataFasciculusmedicineHumansInferior longitudinal fasciculusPromoter Regions GeneticGSK3-β; lithium; bipolar disorder; white matter; cingulum bundle030304 developmental biologybipolar disorderPharmacology0303 health sciencesGlycogen Synthase Kinase 3 betabiologyGenetic VariationMiddle Agedbiology.organism_classification3. Good healthPsychiatry and Mental healthmedicine.anatomical_structurenervous systemlithiumCorticospinal tractSettore BIO/14 - FarmacologiaGSK3-beta lithium bipolar disorder white matter cingulum bundleFemaleOriginal ArticleBrain Gray Mattercingulum bundlePsychologywhite matterNeuroscience030217 neurology & neurosurgeryDiffusion MRI
researchProduct

IRF4 regulates IL-17A promoter activity and controls RORγt-dependent Th17 colitis in vivo

2011

The transcription factor IRF4 is involved in several T-cell-dependent chronic inflammatory diseases. To elucidate the mechanisms for pathological cytokine production in colitis, we addressed the role of the IRF transcription factors in human inflammatory bowel disease (IBD) and experimental colitis.IRF levels and cytokine production in IBD patients were studied as well as the effects of IRF4 deficiency in experimental colitis.In contrast to IRF1, IRF5, and IRF8, IRF4 expression in IBD was augmented in the presence of active inflammation. Furthermore, IRF4 levels significantly correlated with IL-6 and IL-17 mRNA expression and to a lesser extent with IL-22 mRNA expression in IBD. To further …

AdultMaleElectrophoretic Mobility Shift AssayInflammatory bowel diseasePolymerase Chain Reaction03 medical and health sciencesMice0302 clinical medicineCrohn DiseaseRAR-related orphan receptor gammaImmunology and AllergyMedicineAnimalsHumansColitisInterleukin 6Promoter Regions GeneticTranscription factor030304 developmental biology0303 health sciencesCrohn's diseasebiologybusiness.industryInterleukin-6Interleukin-17GastroenterologyMiddle AgedNuclear Receptor Subfamily 1 Group F Member 3medicine.diseaseColitisInflammatory Bowel Diseasesdigestive system diseases3. Good health030220 oncology & carcinogenesisImmunologyInterferon Regulatory Factorsbiology.proteinTh17 CellsColitis UlcerativeFemaleInterleukin 17businessInterferon regulatory factors
researchProduct

Temporal lobe grey matter volume in schizophrenia is associated with a genetic polymorphism influencing glycogen synthase kinase 3-beta activity

2010

At the crossroad of multiple pathways regulating trophism and metabolism, glycogen synthase kinase (GSK)3 is considered a key factor in influencing the susceptibility of neurons to harmful stimuli (neuronal resilience) and is a target for several psychiatric drugs that directly inhibit it or increase its inhibitory phosphorylation. Inhibition of GSK3 prevents apoptosis and could protect against the neuropathological processes associated with psychiatric disorders. A GSK3-beta promoter single-nucleotide polymorphism (rs334558) influences transcriptional strength, and the less active form was associated with less detrimental clinical features of mood disorders. Here we studied the effect of r…

AdultMaleGenotypeApoptosisNeuropathologyBiologyGrey matterGene Expression Regulation EnzymologicTemporal lobe03 medical and health sciencesBehavioral NeuroscienceSuperior temporal gyrusGlycogen Synthase Kinase 30302 clinical medicineGSK-3GeneticsmedicineHumansGenetic Predisposition to DiseasePromoter Regions GeneticGSK3B030304 developmental biology0303 health sciencesGlycogen Synthase Kinase 3 betaPolymorphism GeneticGenetic VariationBrodmann area 21medicine.diseaseTemporal LobeEnzyme Activationmedicine.anatomical_structureNeurologySchizophreniaChronic DiseaseNerve DegenerationSchizophreniaFemaleAtrophyNeuroscience030217 neurology & neurosurgeryGenes, Brain and Behavior
researchProduct

Autoregulatory role of interleukin-10 in hepatitis C patients treated with IFN-alpha.

2004

Interferon-alpha2 (IFN-alpha2) is used as standard treatment of patients with chronic hepatitis C (cHCV), but little is known about the immunomodulatory effects of this cytokine in vivo. We have studied immunologic parameters in freshly isolated peripheral blood mononuclear cells (PBMC) of 26 patients with cHCV 12 h before and 12 h after the first s.c. injection of 5-6 MU IFN-alpha2. In PBMC obtained after IFN injection, a substantial increase in IL-10 production after antigen-specific and nonspecific stimulation was observed, whereas IFN-gamma production and proliferation were significantly diminished compared with PBMC obtained before IFN injection. Patients were stratified according to s…

AdultMaleGenotypeHepacivirusmedicine.medical_treatmentImmunologyStimulationHepacivirusIn Vitro TechniquesInterferon alpha-2Peripheral blood mononuclear cellPolymorphism Single NucleotideInterferon-gammaIn vivoVirologyMedicineHomeostasisHumansInterferon gammaPromoter Regions GeneticAgedbiologyBase Sequencebusiness.industryInterferon-alphaCell BiologyHepatitis CDNAHepatitis C ChronicMiddle Agedmedicine.diseasebiology.organism_classificationRecombinant ProteinsInterleukin-10Interleukin 10CytokineImmunologyLeukocytes MononuclearFemalebusinessmedicine.drugJournal of interferoncytokine research : the official journal of the International Society for Interferon and Cytokine Research
researchProduct

A functional polymorphism in theIL-10 promoter influences the response after vaccination with HBsAg and hepatitis A

2005

The immune response to hepatitis B surface antigen (HBsAg) is mostly genetically determined. Interleukin 10 (IL-10) is a central immunoregulatory cytokine with important effects on B-cells. We have studied the influence of IL-10 promoter polymorphisms on the immune response to HBsAg and hepatitis A vaccination. We vaccinated 202 twin pairs in an open prospective study with a combined recombinant HBsAg/inactivated hepatitis A vaccine. IL-10 promoter polymorphisms were investigated in all individuals and their influence on anti-HBs, and anti-HAV responsiveness was studied. In the multiple regression analysis accounting for smoking, gender, body mass index and age, the ACC haplotype (-1082, -8…

AdultMaleHBsAgHepatitis A vaccineTwinsBiologyAntigenmedicineHumansProspective StudiesAllelePromoter Regions GeneticAntigens ViralHepatitisHepatitis A VaccinesHepatitis B Surface AntigensPolymorphism GeneticHepatologyHaplotypevirus diseasesHepatitis Amedicine.diseaseVirologydigestive system diseasesInterleukin-10VaccinationImmunologyFemaleHepatology
researchProduct

Differential association of polymorphisms in the TNFalpha region with psoriatic arthritis but not psoriasis.

2002

To investigate the potential association of tumour necrosis factor alpha (TNFalpha) microsatellite and promoter alleles with psoriatic arthritis (PsA).DNA from 89 white patients with PsA, 65 patients with psoriasis, and 99 healthy white controls was investigated for two TNFalpha promoter (-238 and -308) and three microsatellite polymorphisms (TNFa, c, and d). Patients had previously been studied by serology for HLA class I antigens and by sequence-specific polymerase chain reaction for DRB1* alleles. In addition, TNFalpha production of Ficoll separated peripheral blood mononuclear cells (PBMC) into culture supernatants after stimulation with lipopolysaccharide, alphaCD3 antibodies, phytohae…

AdultMaleImmunologyArthritisEnzyme-Linked Immunosorbent AssayHuman leukocyte antigenurologic and male genital diseasesPeripheral blood mononuclear cellPolymerase Chain ReactionGeneral Biochemistry Genetics and Molecular BiologyStatistics NonparametricPsoriatic arthritisRheumatologyPsoriasismedicineOdds RatioImmunology and AllergyHumansPsoriasisPromoter Regions GeneticAllelesCells CulturedPhytohaemagglutininAgedAged 80 and overChi-Square DistributionPolymorphism Geneticbiologybusiness.industryTumor Necrosis Factor-alphaHaplotypeArthritis PsoriaticMiddle Agedmedicine.diseaseExtended ReportCase-Control StudiesImmunologybiology.proteinLeukocytes MononuclearFemaleAntibodybusinessMicrosatellite RepeatsAnnals of the rheumatic diseases
researchProduct